Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis
This was a post-hoc analysis of patient-reported outcomes from the LIBERTY AD PEDS randomized, double-blind, placebo-controlled, phase III trial of dupilumab + topical corticosteroids (TCS) in 367 children aged 6–11 years with severe atopic dermatitis (AD). At week 16, significantly more patients tr...
Gespeichert in:
| Veröffentlicht in: | British journal of dermatology (1951) 2023-07, Vol.189 (2), p.238-240 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 240 |
|---|---|
| container_issue | 2 |
| container_start_page | 238 |
| container_title | British journal of dermatology (1951) |
| container_volume | 189 |
| creator | Flohr, Carsten Irvine, Alan D Cork, Michael J Simpson, Eric L Wollenberg, Andreas Deleuran, Mette Praestgaard, Amy Thomas, Ryan B Rossi, Ana B |
| description | This was a post-hoc analysis of patient-reported outcomes from the LIBERTY AD PEDS randomized, double-blind, placebo-controlled, phase III trial of dupilumab + topical corticosteroids (TCS) in 367 children aged 6–11 years with severe atopic dermatitis (AD). At week 16, significantly more patients treated with dupilumab vs. placebo achieved a Patient-Oriented Eczema Measure (POEM) score of 0/1 (‘clear skin’/‘almost clear skin’), and significantly more reported Children’s Dermatology Life Quality Index (CDLQI) scores of 0/1 (‘no effect on life’). Significantly more patients achieved a minimal clinically important difference (≥ six-point reduction) in POEM and in CDLQI. Dupilumab (vs. placebo) + TCS resulted in clinically meaningful improvements in patients’ assessment of AD symptoms and quality of life. |
| doi_str_mv | 10.1093/bjd/ljad124 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2807917607</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2807917607</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-233488ecb6ddc1c1438e95de0f1577bcfb8561d8f90ea13e0b1a00ff76b297263</originalsourceid><addsrcrecordid>eNo9kD1vFDEURS1ERJZARY9cIqEh79k79kyJEghIkdKEeuSxn1mvPB-xPYm2o6HiX-aXMFEWqlfco3v1DmPvED4htPK837vzuDcOxfYF26BUdSVQypdsAwC6glbJU_Y65z0ASqjhFTuVGgVosd2wP5fLHOIymJ6HYU7TPWU-mxJoLFWieUqFHM-HYS7TkLkZHd-RiWW3htE8ZXeLiaEc-OR5DJ54GLndhegSjdz8XAFVIT7--n0gkzJ_CGXHM91TIm7KNAfLHaVhHSwhv2En3sRMb4_3jP34-uX24lt1fXP1_eLzdWWlUKUSUm6bhmyvnLNocSsbamtH4LHWure-b2qFrvEtkEFJ0KMB8F6rXrRaKHnGPjz3rv_eLZRLN4RsKUYz0rTkTjSgW9QK9Ip-fEZtmnJO5Ls5hcGkQ4fQPdnvVvvd0f5Kvz8WL_1A7j_7T7f8CyUJhOo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2807917607</pqid></control><display><type>article</type><title>Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Flohr, Carsten ; Irvine, Alan D ; Cork, Michael J ; Simpson, Eric L ; Wollenberg, Andreas ; Deleuran, Mette ; Praestgaard, Amy ; Thomas, Ryan B ; Rossi, Ana B</creator><creatorcontrib>Flohr, Carsten ; Irvine, Alan D ; Cork, Michael J ; Simpson, Eric L ; Wollenberg, Andreas ; Deleuran, Mette ; Praestgaard, Amy ; Thomas, Ryan B ; Rossi, Ana B</creatorcontrib><description>This was a post-hoc analysis of patient-reported outcomes from the LIBERTY AD PEDS randomized, double-blind, placebo-controlled, phase III trial of dupilumab + topical corticosteroids (TCS) in 367 children aged 6–11 years with severe atopic dermatitis (AD). At week 16, significantly more patients treated with dupilumab vs. placebo achieved a Patient-Oriented Eczema Measure (POEM) score of 0/1 (‘clear skin’/‘almost clear skin’), and significantly more reported Children’s Dermatology Life Quality Index (CDLQI) scores of 0/1 (‘no effect on life’). Significantly more patients achieved a minimal clinically important difference (≥ six-point reduction) in POEM and in CDLQI. Dupilumab (vs. placebo) + TCS resulted in clinically meaningful improvements in patients’ assessment of AD symptoms and quality of life.</description><identifier>ISSN: 0007-0963</identifier><identifier>EISSN: 1365-2133</identifier><identifier>DOI: 10.1093/bjd/ljad124</identifier><identifier>PMID: 37120724</identifier><language>eng</language><publisher>England</publisher><ispartof>British journal of dermatology (1951), 2023-07, Vol.189 (2), p.238-240</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c326t-233488ecb6ddc1c1438e95de0f1577bcfb8561d8f90ea13e0b1a00ff76b297263</citedby><cites>FETCH-LOGICAL-c326t-233488ecb6ddc1c1438e95de0f1577bcfb8561d8f90ea13e0b1a00ff76b297263</cites><orcidid>0000-0003-4428-2428 ; 0000-0003-4884-6286 ; 0000-0003-0177-8722 ; 0000-0003-0593-9925 ; 0000-0003-0853-0252 ; 0000-0002-9048-2044 ; 0000-0002-1141-2073 ; 0000-0001-5345-678X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37120724$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Flohr, Carsten</creatorcontrib><creatorcontrib>Irvine, Alan D</creatorcontrib><creatorcontrib>Cork, Michael J</creatorcontrib><creatorcontrib>Simpson, Eric L</creatorcontrib><creatorcontrib>Wollenberg, Andreas</creatorcontrib><creatorcontrib>Deleuran, Mette</creatorcontrib><creatorcontrib>Praestgaard, Amy</creatorcontrib><creatorcontrib>Thomas, Ryan B</creatorcontrib><creatorcontrib>Rossi, Ana B</creatorcontrib><title>Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis</title><title>British journal of dermatology (1951)</title><addtitle>Br J Dermatol</addtitle><description>This was a post-hoc analysis of patient-reported outcomes from the LIBERTY AD PEDS randomized, double-blind, placebo-controlled, phase III trial of dupilumab + topical corticosteroids (TCS) in 367 children aged 6–11 years with severe atopic dermatitis (AD). At week 16, significantly more patients treated with dupilumab vs. placebo achieved a Patient-Oriented Eczema Measure (POEM) score of 0/1 (‘clear skin’/‘almost clear skin’), and significantly more reported Children’s Dermatology Life Quality Index (CDLQI) scores of 0/1 (‘no effect on life’). Significantly more patients achieved a minimal clinically important difference (≥ six-point reduction) in POEM and in CDLQI. Dupilumab (vs. placebo) + TCS resulted in clinically meaningful improvements in patients’ assessment of AD symptoms and quality of life.</description><issn>0007-0963</issn><issn>1365-2133</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNo9kD1vFDEURS1ERJZARY9cIqEh79k79kyJEghIkdKEeuSxn1mvPB-xPYm2o6HiX-aXMFEWqlfco3v1DmPvED4htPK837vzuDcOxfYF26BUdSVQypdsAwC6glbJU_Y65z0ASqjhFTuVGgVosd2wP5fLHOIymJ6HYU7TPWU-mxJoLFWieUqFHM-HYS7TkLkZHd-RiWW3htE8ZXeLiaEc-OR5DJ54GLndhegSjdz8XAFVIT7--n0gkzJ_CGXHM91TIm7KNAfLHaVhHSwhv2En3sRMb4_3jP34-uX24lt1fXP1_eLzdWWlUKUSUm6bhmyvnLNocSsbamtH4LHWure-b2qFrvEtkEFJ0KMB8F6rXrRaKHnGPjz3rv_eLZRLN4RsKUYz0rTkTjSgW9QK9Ip-fEZtmnJO5Ls5hcGkQ4fQPdnvVvvd0f5Kvz8WL_1A7j_7T7f8CyUJhOo</recordid><startdate>20230717</startdate><enddate>20230717</enddate><creator>Flohr, Carsten</creator><creator>Irvine, Alan D</creator><creator>Cork, Michael J</creator><creator>Simpson, Eric L</creator><creator>Wollenberg, Andreas</creator><creator>Deleuran, Mette</creator><creator>Praestgaard, Amy</creator><creator>Thomas, Ryan B</creator><creator>Rossi, Ana B</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4428-2428</orcidid><orcidid>https://orcid.org/0000-0003-4884-6286</orcidid><orcidid>https://orcid.org/0000-0003-0177-8722</orcidid><orcidid>https://orcid.org/0000-0003-0593-9925</orcidid><orcidid>https://orcid.org/0000-0003-0853-0252</orcidid><orcidid>https://orcid.org/0000-0002-9048-2044</orcidid><orcidid>https://orcid.org/0000-0002-1141-2073</orcidid><orcidid>https://orcid.org/0000-0001-5345-678X</orcidid></search><sort><creationdate>20230717</creationdate><title>Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis</title><author>Flohr, Carsten ; Irvine, Alan D ; Cork, Michael J ; Simpson, Eric L ; Wollenberg, Andreas ; Deleuran, Mette ; Praestgaard, Amy ; Thomas, Ryan B ; Rossi, Ana B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-233488ecb6ddc1c1438e95de0f1577bcfb8561d8f90ea13e0b1a00ff76b297263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Flohr, Carsten</creatorcontrib><creatorcontrib>Irvine, Alan D</creatorcontrib><creatorcontrib>Cork, Michael J</creatorcontrib><creatorcontrib>Simpson, Eric L</creatorcontrib><creatorcontrib>Wollenberg, Andreas</creatorcontrib><creatorcontrib>Deleuran, Mette</creatorcontrib><creatorcontrib>Praestgaard, Amy</creatorcontrib><creatorcontrib>Thomas, Ryan B</creatorcontrib><creatorcontrib>Rossi, Ana B</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of dermatology (1951)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Flohr, Carsten</au><au>Irvine, Alan D</au><au>Cork, Michael J</au><au>Simpson, Eric L</au><au>Wollenberg, Andreas</au><au>Deleuran, Mette</au><au>Praestgaard, Amy</au><au>Thomas, Ryan B</au><au>Rossi, Ana B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis</atitle><jtitle>British journal of dermatology (1951)</jtitle><addtitle>Br J Dermatol</addtitle><date>2023-07-17</date><risdate>2023</risdate><volume>189</volume><issue>2</issue><spage>238</spage><epage>240</epage><pages>238-240</pages><issn>0007-0963</issn><eissn>1365-2133</eissn><abstract>This was a post-hoc analysis of patient-reported outcomes from the LIBERTY AD PEDS randomized, double-blind, placebo-controlled, phase III trial of dupilumab + topical corticosteroids (TCS) in 367 children aged 6–11 years with severe atopic dermatitis (AD). At week 16, significantly more patients treated with dupilumab vs. placebo achieved a Patient-Oriented Eczema Measure (POEM) score of 0/1 (‘clear skin’/‘almost clear skin’), and significantly more reported Children’s Dermatology Life Quality Index (CDLQI) scores of 0/1 (‘no effect on life’). Significantly more patients achieved a minimal clinically important difference (≥ six-point reduction) in POEM and in CDLQI. Dupilumab (vs. placebo) + TCS resulted in clinically meaningful improvements in patients’ assessment of AD symptoms and quality of life.</abstract><cop>England</cop><pmid>37120724</pmid><doi>10.1093/bjd/ljad124</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0003-4428-2428</orcidid><orcidid>https://orcid.org/0000-0003-4884-6286</orcidid><orcidid>https://orcid.org/0000-0003-0177-8722</orcidid><orcidid>https://orcid.org/0000-0003-0593-9925</orcidid><orcidid>https://orcid.org/0000-0003-0853-0252</orcidid><orcidid>https://orcid.org/0000-0002-9048-2044</orcidid><orcidid>https://orcid.org/0000-0002-1141-2073</orcidid><orcidid>https://orcid.org/0000-0001-5345-678X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0963 |
| ispartof | British journal of dermatology (1951), 2023-07, Vol.189 (2), p.238-240 |
| issn | 0007-0963 1365-2133 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2807917607 |
| source | Oxford University Press Journals All Titles (1996-Current) |
| title | Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T23%3A11%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dupilumab%20improves%20patient-reported%20symptoms%20and%20health-related%20quality%20of%20life%20in%20children%20aged%206-11%E2%80%85years%20with%20severe%20atopic%20dermatitis&rft.jtitle=British%20journal%20of%20dermatology%20(1951)&rft.au=Flohr,%20Carsten&rft.date=2023-07-17&rft.volume=189&rft.issue=2&rft.spage=238&rft.epage=240&rft.pages=238-240&rft.issn=0007-0963&rft.eissn=1365-2133&rft_id=info:doi/10.1093/bjd/ljad124&rft_dat=%3Cproquest_cross%3E2807917607%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2807917607&rft_id=info:pmid/37120724&rfr_iscdi=true |